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Abstract
Background
Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious cause of blind-
ness worldwide. Yearly azithromycin mass drug administration (MDA) plays a central role in
efforts to eliminate blinding trachoma as a public health problem. Programmatic decision-
making is currently based on the prevalence of the clinical sign “trachomatous inflamma-
tion-follicular” (TF) in children. We sought to test alternative tools for trachoma surveillance
based on serology in the 12-year cohort of Kahe Mpya, Rombo District, Tanzania, where oc-
ular chlamydial infection was eliminated with azithromycin MDA by 2005.
Methodology and Principal Findings
The present study was a community-based cross-sectional survey in Kahe Mpya. Of 989
residents, 571 people aged 6 months to 87 years were enrolled: 58% of the total population
and 73% of 1–9 year olds, the key WHO indicator age group. Participants were examined
for TF, had conjunctival swabs collected for nucleic acid amplification test (NAAT)-based
detection of Ct, and blood collected for analysis of antibodies to the Ct antigens pgp3 and
CT694 by multiplex bead-based immunoassay. Seroconversion rate was used to estimate
changes in the force of infection in a reversible catalytic model. No conjunctival swabs test-
ed positive for Ct infection by NAAT. Among 1–9 year olds, TF prevalence was 6.5%,
whereas only 3.5% were seropositive. Force of infection modelling indicated a 10-fold de-
crease in seroconversion rate at a time corresponding to MDA commencement. Without
baseline serological data, the inferences we can make about antibody status before MDA
and the longevity of the antibody response are limited, though our use of catalytic modelling
overcomes some of these limitations.
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Conclusions/Significance
Serologic tests support NAAT findings of very low to zero prevalence of ocular Ct in this
community and have potential to provide objective measures of transmission and useful
surveillance tools for trachoma elimination programs.
Author Summary
Trachoma is the leading infectious cause of blindness. The infectious agent, Chlamydia
trachomatis, can be treated with a single oral dose of azithromycin. Donated drug is a cor-
nerstone of programs dedicated to the elimination of trachoma as a public health problem.
Azithromycin is given to the entire district for 3–5 years when 10% or more of 1–9 year-olds
in the district have signs of a defined follicular conjunctivitis in one or both eyes. However,
follicles can be difficult to reliably diagnose and can be caused by other pathogens, especially
in settings with low trachoma prevalence. More sensitive and specific ways to assess commu-
nities for trachoma transmission at program endpoints are needed. Herein we examined an-
tibody responses in children living in a community in Tanzania born after stopping drug
treatment 10 years previously. Low antibody levels (3.5% in 1–9 year-olds) reflected the lack
of ocular chlamydial infection in these children. We also modelled the data to show that
changes in age-specific antibody prevalence occurred when the mass drug treatment
stopped. These data suggest that the age-specific prevalence of antibody responses may be of
use to programs seeking to demonstrate the impact of interventions against trachoma.
Introduction
Trachoma, caused by the bacterium Chlamydia trachomatis (Ct), is the leading infectious cause
of blindness worldwide [1]. Infection can manifest clinically in a number of ways, including fol-
licular conjunctivitis, classified as “trachomatous inflammation-follicular” (TF) in the WHO
simplified grading system [2] if five or more follicles are present in the central upper tarsal con-
junctiva; and/or inflammatory thickening, classified as “trachomatous inflammation-intense”
(TI) if more than half of the deep tarsal vessels are obscured. Repeated infections can lead to
conjunctival scarring (TS) and trichiasis (TT), in which in-turned eyelashes rub against the
globe and may result in visual impairment or blindness caused by corneal opacity (CO) [3].
Azithromycin mass drug administration (MDA), recommended where the prevalence of TF
is10% in children aged 1–9 years, is a critical component of the strategy for Global Elimina-
tion of Trachoma by 2020 (GET2020) [4]. The current WHO endpoint for cessation of com-
munity-based antibiotic treatment is a TF prevalence in 1–9 year-olds of<5%.
Prevalence surveys illustrate that signs of active trachoma, TF and TI, exceed Ct infection
rates. Follicular or intense conjunctivitis may be caused by non-chlamydial bacteria, with the
relative importance of this phenomenon probably increasing after populations begin to receive
azithromycin MDA [5]. Furthermore, the examination process can be difficult to standardize
[6–9]; inter-observer agreement is often sub-optimal. The poor correspondence between signs
and infection—seen at both individual and community level—is problematic, given that field
grading is the basis of public health decision-making [5, 10].
As trachoma elimination efforts are intensified globally and interventions move populations
towards trachoma elimination goals, the availability of a post-elimination surveillance methodol-
ogy with greater reliability than clinical examination will become increasingly important to allow
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programs to identify and respond to recrudescent infection. Recent efforts to evaluate serology as
a viable option for post-MDA surveillance identified tests using two previously-described chla-
mydial antigens, pgp3 and CT694, as having high sensitivity to detect current ocular infection,
and high specificity using non-endemic controls [11]. The age-specific prevalence of serological
responses to Ct antigens at community level could provide an informative proxy measure of in-
tensity of transmission and an early indicator of transmission recrudescence. This study there-
fore examined the use of serological tools for monitoring and evaluation in a post-MDA setting
by assessing the age-specific prevalence of signs of trachoma and Ct-specific antibody responses
within a community in which MDA ceased in 2002 and ocular Ct infection was subsequently
found to have been eliminated in 2005 [12].
Materials and Methods
Study area
This study was conducted in the Tanzanian community of Kahe Mpya, Rombo District. Kahe
Mpya consists of approximately 250 households, with a population (in July 2012) of 989. A Kili-
manjaro Christian Medical College (KCMC)/London School of Hygiene & Tropical Medicine
(LSHTM)/Huruma Hospital collaboration has been conducting trachoma research in this com-
munity since 2000 [13, 14]. High coverage azithromycin MDA was delivered in 2000 and 2002,
and topical tetracycline ointment treatment was given, at intervals between 2000 and 2005, to in-
dividuals with active trachoma; elimination of ocular Ct infection by 2005 was previously docu-
mented [12]. Ethical approval to carry out this research was obtained from the ethics committees
at LSHTM (UK), Centers for Disease Control and Prevention (USA), KCMC / Tumaini Univer-
sity, and the National Institute for Medical Research (TZ). All adults provided written informed
consent, and for children under 18, the consent of a parent or guardian was obtained.
All Kahe Mpya residents were invited by village leaders to a series of central locations,
where those consenting to the study underwent examination of both eyes by a trained, highly
experienced ophthalmic nurse known to the community, using binocular loupes (magnifica-
tion ×25) and a torch. Signs of trachoma were graded according to the WHO simplified grad-
ing system [2]. After examination, swabs were collected from the everted upper eyelid of the
right eye using a sterile polyester-tipped-swab by passing the swab across the conjunctiva four
times. Swabs were placed into sterile polypropylene tubes and kept at 4°C until frozen (-20°C).
Individuals with signs of active trachoma were given a tube of 1% tetracycline eye ointment
free of charge and instructed to apply it daily to both eyes for six weeks. Fingerprick blood was
collected by Tanzanian registered physicians onto filter paper with six circular extensions, cali-
brated so that each extension absorbed 10μl of whole blood (TropBio Pty Ltd, Townsville,
Queensland, Australia). Each filter paper was air-dried then individually placed in a zip-lock
bag and frozen (-20°C). Each sample was affixed with a pre-printed bar-coded label that linked
all samples from an individual but had no other patient identifier.
Multiplex analysis for serum IgG
Dried blood spots were shipped to the Centers for Disease Control and Prevention in Atlanta
GA, USA, for detection of IgG antibodies against the previously described chlamydial proteins
pgp3 and CT694, on the Luminex platform, using previously defined cut-offs for positivity
[11]. Briefly, serum eluted from dried blood spots was incubated with microbeads coupled to
the antigens of interest, then excess serum washed off and bound antibody detected with an
anti-human IgG and anti-human IgG4 biotinylated detection antibody, and finally detected
using streptavidin-conjugated to phycoerythrin (PE). The fluorescent signal emitted by bound
PE was converted to a median fluorescence intensity (MFI) with background from the blank
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subtracted out (MFI-BG). For pgp3, a MFI-BG value of 1024 was established as the low-limit
value for positivity, with an indeterminate range of 1024 to 5998. For CT694, a MFI-BG value
of 232 was established as the low-limit value for positivity, with an indeterminate range of 232
to 1982 [11].
Force of infection modelling
To examine the change in transmission following MDA, we used seroconversion rate (SCR) to
estimate the force of infection by fitting a simple reversible catalytic model to the measured sero-
prevalence, stratified into yearly age-groups, using maximum likelihood methods [15]. For these
models only individuals aged one year and over were included to remove the effect of maternally
derived antibodies in infants. Evidence for temporal changes in SCR was explored by fitting
models in which the SCR was allowed to change at a single time-point. The significance of the
change was identified using likelihood ratio tests against models with no change, and profile like-
lihoods were plotted to determine confidence intervals for the estimated time of the change.
Detection of conjunctival swab C. trachomatis DNA
Samples were processed at the LSHTM and tested in pools of five using the Roche CT/NG
Amplicor kit (Roche Molecular Systems, Pleasanton, CA, USA), with the intention of re-testing
positive pools as individual samples [16–18]. Manufacturer’s instructions were followed except
for sample extraction where a previously published protocol was used[14]. Two Ct positive and
two Ct negative processing controls were run with each batch of specimens. According to the
manufacturer’s directions, the Amplicor test was positive if the optical density read at 450 nm
was08, negative if the signal was<02, and equivocal if in-between. All equivocal tests were
re-tested in duplicate, and only graded positive if at least one test was positive.
Data entry and statistical analysis
All samples were analysed in anonymous fashion through the use of non-sequential sample
codes linked only to patient records through the data collection sheet. Statistical analysis was
carried out using STATA 12 and GraphPad Prism (version 6.0).
Results
Demographic information
The population and study population structure of Kahe Mpya sub-village is summarized in
Table 1, based on census data collected in July 2012 for this study. From the total 989 residents
of Kahe Mpya sub-village, 575 (58.1% coverage) people aged 0.2–87.6 years (median age 12.6,
Table 1) participated in the study.
Age-specific prevalence of clinical signs of trachoma
The overall prevalence of active trachoma (TF,TI or both) in the examined population (n =
571; four individuals refused clinical exams) was 4.6%, with 21.5% exhibiting signs of scarring
trachoma (TS/TT/CO, Table 2). There were no WHO simplified grading scheme signs of tra-
choma in 766% of the study group. The prevalence of TF amongst the WHO index age group
(ages 1–9 years) was 65% (Table 2). Only one individual 10 years had TF. TS was absent in
those<10 years, but was observed in all age groups>10 years (Table 2). TT was present only
in individuals>20 years of age, with an overall population prevalence of 1% (Table 2). CO was
only diagnosed in 2 individuals (04% of study participants), both of whom were over 70 years
old (Table 2).
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Age-specific seroprevalence of trachoma and Ct infection
Overall, 33.8% of participants were seropositive against at least one antigen (Fig. 1A). Seroposi-
tivity increased with age. By age 40, over 90% of participants tested positive to at least one anti-
gen (pgp3 alone, CT694 alone, or both pgp3 and CT694, black squares, Fig. 1A), and over 60%
Table 1. Population structure of Kahe-Mpya and the study population.
Kahe Mpya sub-village
Total population 989
Males [%] 481 [48.6]
Females [%] 508 [51.4]
Population structure of study participants
Total number of participants 575
Males [%] 242 [42.1]
Females [%] 333 [57.9]
Age range in years [median] 0.2–87.6 [12.6]
doi:10.1371/journal.pntd.0003555.t001
Table 2. Age-speciﬁc prevalence of clinical signs of trachoma.
Age (years) TF [%] TI [%] TS [%] TT [%] CO [%] N
<1 0 0 0 0 0 18
1 3 [20] 1 [7] 0 0 0 15
2 2 [8] 1 [4] 0 0 0 24
3 4 [14] 0 0 0 0 29
4 0 0 0 0 0 26
5 1 [6] 0 0 0 0 18
6 0 0 0 0 0 23
7 2 [8] 1 [4] 0 0 0 25
8 1 [9] 0 0 0 0 11
9 0 0 0 0 0 29
10–20 0 2[1] 8[5] 0 0 161
20–30 1 [4] 1 [4] 6 [25] 1 [4] 0 24
30–40 0 0 7 [19] 1 [3] 0 36
40–50 0 0 19 [61] 0 0 31
50–60 0 1 [2] 34 [74] 1 [2] 0 46
60–70 0 2 [6] 19 [58] 1 [3] 0 33
70–80 0 2 [12] 16 [94] 2 [12] 1 [6] 17
80–90 0 1 [20] 5 [100] 0 1 [20] 5
TOTAL 14 [2.5] 12 [2.1] 114 [20.0] 6 [1.1] 2 [0.4] 571
TOTAL (0–9) 13 [6.0] 3 [1.4] 0 0 0 218
TOTAL (1–9) 13 [6.5] 3 [1.5] 0 0 0 200
TF = trachomatous inﬂammation—follicular
TI = trachomatous inﬂammation—intense
TS = trachomatous scarring
TT = trachomatous trichiasis
CO = corneal opacity.
Numbers represent N for each group, numbers in parentheses represent % of individuals in each age group with the respective clinical sign.
doi:10.1371/journal.pntd.0003555.t002
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tested positive to both antigens (Fig. 1A, red squares); this trend continued to the oldest age
groups (Fig. 1A). The MFI also increased with age (Fig. 1B). Of 200 children aged 1–9, seven
(3.5%) had antibody responses to one antigen, whereas only two (1%) had antibody responses
to both antigens (Fig. 1C). Five of the seven samples with pgp3 reactivity fell into the indeter-
minate range, as did both of the CT694-reactive samples (Fig. 1C). Samples from six of the
seven 1–9 year olds testing positive by serology were re-tested with separate pgp3 and CT694
bead sets and data replicated the original results (S1 Table).
None of the ocular swabs tested positive by NAAT.
Fig 1. Antibody responses toCt antigens 10 years after MDA cessation. A. Age-prevalence curves for
antibody responses grouped by decade. Black squares represent individuals with any antibody-positive test (to
pgp3 alone, CT694 alone, or both antigens), and red squares represent responses positive to both pgp3 and
CT694. B. Plots show box-and-whiskers graph (min-max) of MFI-BG against age ranges grouped by decade for
antibodies against pgp3 (left) and CT694 (right). C. Plots show age against MFI-BG for children aged 1–9. Each
dot represents a single individual. Note the differences in the y-axis scales for pgp3 (left) and CT694 (right).
Indeterminate range is shaded. Horizontal lines indicate cutoffs for antibody positivity. Ag = antigen.
doi:10.1371/journal.pntd.0003555.g001
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Force of infection modelling
When a seroconversion model, which allowed for a single change in SCR, was fitted to the
data, the best fit was provided by a change in transmission between 10–15 years previously,
consistent with the timing of MDA in the years 2000 and 2002 (Fig. 2A for antibody responses
to either antigen; responses to individual antigens gave similar profiles). We chose a model in
which SCR changed 10 years previously, which had a better fit than the model that assumed
the SCR had remained constant (Fig. 2B). The change in SCR before and after this change
point is approximately a 10-fold reduction, from a pre-MDA SCR of 0.0448 (95%CI 0.0373–
0.0537) to a post-MDA SCR of 0.004 (95%CI 0.0024–0.0093)].
Discussion
Global efforts toward the elimination of blinding trachoma are being rapidly intensified, thanks
to strong donor interest. As programs reduce the prevalence of disease and infection, robust
surveillance systems will become crucial to detect any recrudescence in populations living in
post-elimination settings. In this study, we examined the use of serological tools for trachoma
in a post-MDA setting. The virtual absence of antibody responses in children born after MDA-
precipitated elimination of ocular Ct infection reflects the lack of Ct transmission (as suggested
by NAAT) and provides the first evidence that serological monitoring of antibody responses
could be viable for informing programmatic decisions in the surveillance phase. Force of infec-
tion modelling shown here strongly supports the hypothesis that reductions in transmission in
this community coincident with the commencement of azithromycin MDA were reflected in
changes in Ct seroconversion rate. This suggests that serology could have a very useful pro-
grammatic role even in the absence of complete transmission interruption.
Several factors could contribute to the presence of signs of active trachoma in a community
with low or no transmission of conjunctival Ct. First, the WHO simplified grading system em-
ploys strict criteria for diagnosis, but was designed for simplicity rather than specificity. Our
Fig 2. Force of infectionmodelling of seroconversion rates before and after MDA. A. Maximum likelihood fits from reversible catalytic equilibriummodel
for antibody responses either pgp3 or CT694 is shown. X-axis represents the time in years that each model has a change point. The y-axis is the log-
likelihoods from each model where log-likelihoods are rescaled against a maximum of 0 and a log-likelihood above -2 is an approximate 95% confidence
interval when the change occurred. B. A model in which SCR changed 10 years previously, to represent the time at which MDA ceased, had a better fit than
the model that assumed the SCR had remained constant (likelihood ratio test X2 = 45.4 p,0.0001). The triangles represent deciles of observed seroprevalence;
the solid blue line represents the predicted values based on themodel with dotted lines and the 95%CI.
doi:10.1371/journal.pntd.0003555.g002
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grader was, however, well trained, highly experienced, and internationally certified, and we are
confident of the accuracy of his judgements about the presence or absence of TF. Second, the
natural histories of infection and disease differ, with signs arising weeks after infection has
been acquired and persisting for weeks or months after infection clears. At the population
level, the prevalence of infection declines more rapidly than the prevalence of TF following
MDA [12, 19, 20] with some studies showing that TF persists at levels>10% within the popu-
lation for months or years after infection has subsided [21, 22]. Finally, evidence suggests that,
in low-trachoma-prevalence settings, the majority of TF is associated with conjunctival infec-
tion with non-chlamydial bacteria, including S. pneumoniae and H. influenzae [5, 23]. Non-
bacterial causes of conjunctivitis such as adenovirus [24] may also contribute to TF clinical di-
agnoses in low-trachoma-prevalence settings. The use of photographs to validate field exams is
becoming increasingly common but we have not found it to be reliable [25] and did not incor-
porate it into this study.
Antibodies against the Ct antigens among 1–9 years old in this study were present at very
low prevalence and in general at very low densities. This is in stark contrast to areas of active
transmission in which seropositivity exceeds rates of clinical disease, as would be expected
from long-lived antibody responses.[26] and has high sensitivity for ocular infection,[11, 26] In
the present study, antibody responses in 1–9 year olds may be Ct-specific, resulting from ocular
or respiratory Ct infection acquired at birth from a mother with genital tract infection [27], or
from ocular infection acquired outside the village or in the village itself. Because the target for
trachoma programs is not the complete interruption of transmission, it would not be an indica-
tion of programmatic failure to find ongoing low-level transmission in a community. However,
it should also be noted that the previously determined specificity limits of this serological assay
were 96–98%, such that the 35% of 1–9 year old samples testing positive may be false positives
[11].
Because data were collected from a single community and enrolment was lower than antici-
pated (primarily due to lack of availability of participants at the time of enrolment, as many
adults were working outside of the community at the time of the study), additional studies in
post-MDA settings will be needed to confirm the generalizability of our data. While the overall
study enrolment was 58.1% of the total population, enrolment of 1–9 year olds, the key WHO
indicator age group, was approximately 72.9% (extrapolated from 2010 census data). Without
baseline serology data, the inferences we can make about antibody status before MDA, the lon-
gevity of antibodies, and how antibody titers change over time in relation to one another are re-
stricted, although our application of catalytic modelling overcomes some of these limitations.
While comparing baseline to post-MDA antibody levels would be optimal, programs using se-
rological tests as monitoring tools for intervention impact would need to do so in populations
from whom baseline serological data will be absent. Antibody responses will therefore be most
useful as surveillance tools by focusing analyses on children born after initiation or cessation of
interventions. The data presented in the current study show the power of antibody-based sur-
veillance in children born after cessation of an MDA program, data supported by the historical
documentation of interruption of ocular Ct transmission in this community.
Antibody responses represent exposure to infection and, when integrated with age, repre-
sent exposure over time; this can be done simply by applying a catalytic conversion model.
SCR has been used widely in a range of infectious diseases [28, 29], most recently and exten-
sively for malaria, for which SCR has been shown to correlate with the force of infection [15,
30, 31]. Fitting models with two SCRs enabled the measurement of changes in force of infec-
tion. SCR suggests a 10-fold decrease in the force of infection from approximately 5% serocon-
version in the population per year prior to MDA, to approximately 0.5% after MDA, which
closely approximates the 0% ocular infection prevalence seen in this study. Catalytic models
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can be refined by using serological data from multiple settings, pre- and post-MDA, to further
validate the use of serological testing for programs.
Serological tests for measuring antibodies in children may represent the best option for
monitoring transmission because of the potential for greater sensitivity as population-based
markers of exposure. Additionally, they provide an objective marker, relatively free of observer
bias (unlike examination for clinical signs), and are likely to be lower in cost than NAATs and
provide data on cumulative exposure to the bacterium. Programmatically, such an assay could
be used in the same way that antigen detection assays are used in surveillance for lymphatic fil-
ariasis elimination programs, and seroprevalence has been proposed for malaria control and
elimination programs [30, 32]; that is, to document reductions in the force of transmission.
With the recent increased emphasis on a more horizontal approach to disease control, given
similarities in control methods (particularly periodic MDA) and the geographical overlap be-
tween trachoma and other NTDs, integration across NTD programs is the next step [33]. This
will provide economic and pragmatic benefits, as a multiplexed serological tool has the poten-
tial to map, monitor and evaluate several diseases simultaneously, facilitating efforts to achieve
long-term elimination goals.
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